Barclays
HRTX icon

Barclays’s Heron Therapeutics HRTX Stock Holding History

Barclays’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,300
Closed -$31K – 6272
2019
Q4 		$31K Buy
1,300
+1,100
+550% +$24.3K ﹤0.01% 5881
2019
Q3 		$4K Buy
+200
New +$3.68K ﹤0.01% 6479
2019
Q1 		– Sell
-9,300
Closed -$241K – 7141
2018
Q4 		$241K Sell
9,300
-39,200
-81% -$1.08M ﹤0.01% 4448
2018
Q3 		$1.53M Buy
48,500
+43,400
+851% +$1.62M ﹤0.01% 3194
2018
Q2 		$198K Buy
5,100
+4,500
+750% +$143K ﹤0.01% 4732
2018
Q1 		$17K Sell
600
-2,800
-82% -$63.5K ﹤0.01% 6488
2017
Q4 		$62K Buy
3,400
+1,900
+127% +$31K ﹤0.01% 5613
2017
Q3 		$24K Buy
1,500
+500
+50% +$7.84K ﹤0.01% 5719
2017
Q2 		$14K Hold
1,000
– – ﹤0.01% 5935
2017
Q1 		$15K Buy
+1,000
New +$13.8K ﹤0.01% 5924
2015
Q3 		– Sell
-180,000
Closed -$5.58M – 6922
2015
Q2 		$5.58M Buy
+180,000
New +$3.39M 0.01% 1404

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Barclays's HRTX Position: Q2 2026 in Review

Barclays reduced its Heron Therapeutics (HRTX) stake by 0.41% in Q2 2026, selling an estimated $298 and leaving 91,022 shares worth $38.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4398.

Barclays first reported a position in HRTX in Q2 2014 and has held it in 49 quarters since. The position peaked at $2.25M in Q1 2021. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Barclays held 91,022 shares of Heron Therapeutics worth $38.8K as of Q2 2026.
  • Barclays sold 372 Heron Therapeutics shares in Q2 2026, an estimated $298.
  • Heron Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4398 holding.
  • Barclays first reported a position in Heron Therapeutics in Q2 2014 and has held it in 49 quarters since.
  • Barclays's Heron Therapeutics position peaked at $2.25M in Q1 2021.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.